Sai Parenteral's Board Approves AUD 1.75M Loan to Australian Subsidiary

Sai Parenteral's Limited Board of Directors has approved a significant financial assistance proposal for its wholly owned subsidiary, Sai Singapore Pte. Ltd., to fund downstream investment in Noumed Pharmaceuticals Pty Limited, Australia. The decision was taken at the board meeting held on April 20, 2026, which commenced at 12:00 Noon and concluded at 02:40 Noon.

Investment Approval Details

The Board approved provision of financial assistance by way of unsecured loan not exceeding AUD 1.75 million or SGD 1.610 million, which is equivalent to INR 11,91,40,000. The loan will be provided to Sai Singapore Pte. Ltd., a wholly owned subsidiary of the company, for downstream funding to Noumed Pharmaceuticals Pty Limited, Australia, which operates as a step-down subsidiary.

Parameter	Details
Loan Amount (AUD)	1.75 million
Loan Amount (SGD)	1.610 million
Loan Amount (INR)	11,91,40,000
Loan Type	Unsecured
Recipient	Sai Singapore Pte. Ltd.
Downstream Beneficiary	Noumed Pharmaceuticals Pty Limited, Australia
Meeting Date	April 20, 2026
Meeting Time	12:00 Noon - 02:40 Noon

Regulatory Compliance and Disclosure

The outcome was disclosed in compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed both BSE Limited (Scrip Code: 544742) and National Stock Exchange of India Limited (Trading Symbol: SAIPARENT, ISIN: INE0H9F01037) about the board decision.

The notice was digitally signed by Anil Kumar Karusala, Chairman and Managing Director (DIN: 01866646), on April 20, 2026, at 14:44:19 +05'30. The information will also be made available on the company's website at www.saiparenterals.com .

Sai Parenteral Limited has notified stock exchanges regarding the authorization of key managerial personnel for regulatory disclosure purposes. The company communicated this development to both BSE Limited and National Stock Exchange of India Limited on April 06, 2026, ensuring compliance with SEBI regulations.

Authorized Personnel Details

Under Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has designated three key managerial personnel as authorized persons for determining materiality of events and making disclosures to stock exchanges.

Sr. No.	Name	Designation
1.	Anil Kumar Karusala	Chairman and Managing Director
2.	Anil Kumar	Chief Financial Officer
3.	Shivali Aggarwal	Company Secretary and Compliance Officer

These authorized persons are severally empowered to determine the materiality of events or information and handle disclosure requirements to stock exchanges on behalf of the company.

Regulatory Compliance

The intimation was formally submitted to the listing departments of both major Indian stock exchanges. BSE Limited, where the company trades under scrip code 544742, and National Stock Exchange of India Limited, where it is listed under the symbol SAIPARENT, received the notification simultaneously.

The communication was digitally signed by Anil Kumar Karusala, Managing Director with DIN 01866646, on April 06, 2026. This authorization framework ensures that the company maintains proper governance structure for regulatory communications and compliance with SEBI's listing obligations.